Overton Confirmation Remains Uncertain After Senate Hearing
FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections.
The Senate Health, Education, Labor and Pensions Committee hearing provided few clear signals about whether several key Republican senators will ultimately support President Trump’s nominee. Overton faced pointed questioning over vaccines, the abortion drug mifepristone and her willingness to exercise independence as FDA commissioner.
The uncertainty is particularly significant because Republicans can afford few defections if Democrats oppose the nomination. HELP Committee Chairman Bill Cassidy (R-LA), who expressed serious reservations about Overton when she was nominated in August, did not use the hearing to announce his support.
According to Axios, Cassidy said after the hearing that he still needed to review Overton's answers and responses to additional questions before deciding whether to support her. Other Republicans also stopped short of committing themselves.
That leaves unanswered not only whether Overton can secure confirmation, but whether the Senate has enough time to complete the process before the November elections.
The Senate's tentative 2026 calendar provides a particularly narrow window. Senators are scheduled to begin a state work period 10/5 that runs through 11/6, leaving little time before the election for the HELP Committee to vote on Overton's nomination and, if approved, send it to the full Senate.
The HELP Committee also has not announced a committee vote on Overton's nomination. Following her 9/24 confirmation hearing, the committee would still have to vote to report the nomination before it could proceed to the full Senate. The situation echoes concerns raised shortly after Overton's nomination.
Steven Grossman, a former HHS official and Senate HELP Committee staffer, told FDA Webview in August that confirmation before the midterms "seems unlikely," noting the limited number of Senate legislative days available and uncertainty about whether all Republican senators would support a rapid confirmation.
Grossman also cautioned that postponing the nomination until a post-election lame-duck session would not necessarily make confirmation easier. Departing senators sometimes do not return for votes or may be reluctant to decide matters they believe should be left to the incoming Congress, he said.
Overton's hearing underscored some of the issues that could complicate her path.
Cassidy questioned whether she would defend scientific evidence when it conflicted with positions taken by the administration. The Louisiana Republican previously criticized Overton's involvement in administration vaccine policy and questioned whether her management experience prepared her to lead FDA.
At Thursday's hearing, Overton said the measles, mumps and rubella vaccine is safe and effective and rejected assertions that it is lethal. She also faced questioning about mifepristone, but provided limited indication of what regulatory actions she might take as commissioner.
Cassidy said in his opening remarks that FDA's next commissioner must ensure that the agency remains the global "gold standard" while addressing regulatory barriers that he said are pushing some biomedical development overseas.
For now, however, the immediate issue is whether Overton's nomination can get through the Senate.
Her hearing satisfied one important procedural step, but it did not produce a committee vote, commitments from pivotal Republican senators or a clear timetable for consideration by the full Senate. With the Senate scheduled to leave Washington in early October, the opportunity to confirm a new FDA commissioner before the midterms is quickly diminishing.